<p>Ovarian cancer (OV) is the most lethal gynaecologic malignancy. Metabolic reprogramming is a distinct feature of cancer and is associated with tumourigenesis and progression. It could be a potential therapeutic target for cancer treatment and a biomarker for assessing cancer prognosis. In this study, we identified metabolic reprogramming-related differentially expressed genes (MRRDEGs) in OV through differential gene expression analysis and conducted a comprehensive characterization of these MRRDEGs. On the basis of the MRRDEGs, we constructed a prognostic risk model that included five model genes for OV. The risk score was an independent prognostic factor that could predict the survival of OV patients. It could classify OV patients into distinct risk groups with significant differences in survival. We observed significant differences between risk groups in terms of biological pathway activity, immune cell infiltration patterns, and immunotherapy responses. Specifically, compared with the high-risk group, the low-risk group had a potentially superior immunotherapy response. These findings significantly advance our understanding of the relationships between metabolic reprogramming and OV pathogenesis, progression, prognosis, and immunotherapy response, laying a foundation for the development of novel biomarkers and therapeutic targets in the future and providing an important reference for the formulation of precision medicine strategies.</p>